
New NCCN guidelines are available for oncologists on treating and counseling patients with small cell lung cancer.

New NCCN guidelines are available for oncologists on treating and counseling patients with small cell lung cancer.

The breakthrough therapy designation marks the agents seventh regulatory designation.

The ASSURE trial is actively recruiting patients with chronic lymphocytic leukemia to receive acalabrutinib in an investigation of its safety and efficacy.

Lyniate Corepoint was selected by Cancer Treatment Centers of American as its strategic interoperability solution to support rapid growth and ongoing innovation initiatives designed to put patients at the center of care.

In an interview with Targeted Oncology™: Jeffrey Miller, MD, discussed the use of NK cell destruction to boost IL-15 efficacy in refractory tumors.

Luhua Wang, MD, discussed the impact that the approval of the CAR T-cell therapy brexucabtagene autoleucel has had on mantle cell lymphoma.

In an interview with Targeted Oncology, Marshall Posner, MD, discusses the use of the HB-201 and HB-202 vaccines in patients with human papillomavirus 16- positive cancers.

A phase 2 study suggests that tipifarnib may be more beneficial for patients with CMML, MDS, or MPNs and RAS pathway mutations than the general population of patients with these disease.

Based on results from the DESTINY-Breast03 clinical trial, trastuzumab deruxtecan has been granted another breakthrough therapy designation by the FDA.

Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the differences between the global and Asian cohorts in the KAMILLA trial (NCT01702571), which evaluates the benefit of trastuzumab emtansine (T-DM1, Kadcyla) in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.

In an interview with Targeted Oncology, Patrick Connor Johnson, MD, discussed the top considerations taken into account by physicians when choosing a third-line therapy for diffuse large B-cell lymphoma.

The FDA has approved brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Treatment with the investigational agent SY-2101 has begun in a phase 3 clinical trial of patients with newly-diagnosed acute promyelocytic leukemia.

Jason Westin, MD, discusses the current standard of care in diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Axi-cel developer seeks to expand Axi-Cel for large B-cell lymphoma application to include the second-line setting.

Here is a look back FDA happenings from September 2021.

PARP inhibitors are a common treatment for ovarian cancer, but mechanisms of resistance have yet to be fully understood.

Positive findings from the phase 3 VISION have led the FDA to grant priority review to 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer.

NUC-1031, a drug for the first-line treatment of patients with advanced biliary tract cancer, has been granted fast track designation by the FDA.

lorida Cancer Specialists & Research Institute has announced the appointment of Michael Diaz, MD as President & Managing Physician.

Phase 2 study results signal benefit of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutant non–small cell lung cancer.

According to phase 1 data from the MagnetisMM-1 trial, elranatamab may be a good treatment option for patients with relapsed/refractory multiple myeloma.

The FDA has approved cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer harboring a BRAF V600E mutation, after prior therapy.

Moshe Levy, MD discusses the ongoing phase 3b study of asciminib in patients with chronic myeloid leukemia in chronic phase.

Principle study investigator Yuliya Mikheeva, MD, PhD, of Saint-Petersburg State University, discussed the combination of dabrafenib and trametinib for the treatment of anaplastic thyroid cancer in an interview with Targeted Oncology.

Srdan Verstovsek, MD, PhD, a professor of Medicine and a hematologic oncologist at the University of Texas MD Anderson Cancer Center, discusses unmet clinical needs in myelofibrosis.

Press Release
Sarah Cannon recently opened its newest drug development unit in collaboration with Florida Cancer Specialists & Research Institute and The University of Central Florida College of Medicine in Lake Nona, Florida.

The Cancer and Aging Research Group calculator is a quick and helpful tool to help assess chemotherapy toxicity in geriatric patients, according to research highlighted in a press release by the Yale School of Medicine.

The FDA has accepted and granted priority review to the supplemental biologics license application for the PD-1 inhibitor cemiplimab-wlc for the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.